Near‑patient solutions NanoDx offers rapid point-of-care and in vitro diagnostic capabilities using a proprietary nanowire biosensor platform, presenting a strong upsell opportunity for clinics, urgent care, and emergency departments seeking faster triage and bedside testing.

TBI and COVID focus Recent leadership and product emphasis on traumatic brain injury and COVID-19 tests signals potential cross‑sell into neurology, sports medicine, trauma centers, and infection control programs that require rapid, onsite biomarker measurements.

Regulatory and reimbursement readiness Product is currently for research use only and FDA clearance is pending; position prospects as early adopter customers and partners who can support clinical validation, data generation, and eventual reimbursement pathways.

Strategic partnerships Existing collaborations with SkyWater Technology and MEMS integration indicate openness to OEM/tech partnerships; target large healthcare device integrators, diagnostic distributors, and hospital system vendors for co‑development or distribution deals.

Growth and leadership Recent leadership appointments and a mid‑sized funding base (revenue under 10M, total funding 38M) suggest a company in growth mode; pursue multi‑site deployments, early access programs, and enterprise pilot opportunities to accelerate market penetration.